Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Treace Medical Concepts (TMCI) Shares Outstanding (Weighted Average) (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed Shares Outstanding (Weighted Average) for 6 consecutive years, with $63.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 1.86% year-over-year to $63.3 million, compared with a TTM value of $63.3 million through Dec 2025, up 1.86%, and an annual FY2025 reading of $63.3 million, up 1.86% over the prior year.
  • Shares Outstanding (Weighted Average) was $63.3 million for Q4 2025 at Treace Medical Concepts, roughly flat from $63.5 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $63.5 million in Q3 2025 and bottomed at $37.9 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $57.6 million, with a median of $61.1 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) skyrocketed 44.84% in 2022, then increased 1.08% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $48.4 million in 2021, then rose by 14.17% to $55.3 million in 2022, then grew by 10.09% to $60.9 million in 2023, then rose by 2.07% to $62.1 million in 2024, then grew by 1.86% to $63.3 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for TMCI at $63.3 million in Q4 2025, $63.5 million in Q3 2025, and $62.8 million in Q2 2025.